An orally available VHL-ERα PROTAC was developed that showed excellent degradation in vitro. When dosing in vivo, the degradation of ERα was lower than expected, due to competitive binding at the ERα binding site between the PROTAC and a linker metabolite.
- Thomas G. Hayhow
- Beth Williamson
- Claire Crafter